Article
Allergy
Tanya M. Laidlaw, Joaquim Mullol, Katharine M. Woessner, Nikhil Amin, Leda P. Mannent
Summary: Patients with CRSwNP and asthma often have severe and recurrent disease with tissue eosinophilia and high IgE levels. The shared pathophysiology between upper and lower airways highlights the importance of systemic treatment targeting type 2 inflammatory pathways.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Health Care Sciences & Services
Eugenio De Corso, Silvia Baroni, Stefano Settimi, Maria Elisabetta Onori, Rodolfo Francesco Mastrapasqua, Eliana Troiani, Giacomo Moretti, Donatella Lucchetti, Marco Corbo, Claudio Montuori, Alessandro Cantiani, Davide Paolo Porru, Simone Lo Verde, Giuseppe Alberto Di Bella, Cristiano Caruso, Jacopo Galli
Summary: This study evaluated the inflammatory load and cytokine profiles in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Two distinct clusters were identified based on cytokine levels and eosinophil count, with IL-5 being the most reliable biomarker for differentiation. This research highlights the potential role of type 2 biomarkers, particularly IL-5, in identifying patients with a more severe phenotype.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Rong-San Jiang, I-Chieh Chen, Yi-Ming Chen, Tzu-Hung Hsiao, Yi-Chen Chen
Summary: This study found that polygenic risk scores developed from European populations can be applied to the Taiwanese population to predict the risk of chronic rhinosinusitis, especially for female patients with nasal polyps.
Article
Allergy
Geoffrey Chupp, Isam Alobid, Njira L. Lugogo, Harsha H. Kariyawasam, Arnaud Bourdin, Adam M. Chaker, Steven G. Smith, Ana R. Sousa, Bhabita Mayer, Robert H. Chan, Andrea Matucci
Summary: In patients with severe chronic rhinosinusitis with nasal polyps, mepolizumab improves treatment response regardless of prior use of systemic corticosteroids. Additionally, mepolizumab reduces the probability of requiring systemic corticosteroids.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Immunology
Mingming Wang, Shuangmei Tang, Xiaoqi Yang, Xinyu Xie, Yang Luo, Shaojuan He, Xuezhong Li, Xin Feng
Summary: This study used bioinformatics approaches to explore the underlying pathogenesis of asthma comorbid with chronic rhinosinusitis with nasal polyps (ACRSwNP). The study identified differentially expressed genes (DEGs) associated with ACRSwNP and constructed a protein-protein interaction (PPI) network to identify key genes. The findings were validated through qRT-PCR and potential drugs for the treatment of ACRSwNP were predicted using the Connectivity Map (CMap) database.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Junhu Tai, Jae-Min Shin, Jaehyung Park, Munsoo Han, Tae Hoon Kim
Summary: Oxidative stress is caused by an imbalance between reactive oxygen species production and the body's antioxidant defense system. It plays a crucial role in regulating the immune response and can contribute to various diseases. Recent studies have found that oxidative stress is important in the pathogenesis and persistence of chronic rhinosinusitis (CRS), attracting the attention of researchers. The relationship between reactive oxygen species and nasal polyp pathology is a key topic of interest. This article reviews the role of oxidative stress in respiratory diseases, specifically CRS, and introduces potential antioxidant therapies for targeted treatment.
Article
Allergy
Julie A. Poposki, Aiko Klingler, Whitney W. Stevens, Lydia A. Suh, Bruce K. Tan, Anju T. Peters, Hiam Abdala-Valencia, Leslie C. Grammer, Kevin C. Welch, Stephanie S. Smith, David B. Conley, Robert C. Kern, Robert P. Schleimer, Atsushi Kato
Summary: This study found that neutrophils accumulate and are highly activated in CRSwNP in Western populations, playing a significant role in the inflammation. This finding has important implications for the pathogenesis and treatment of CRSwNP in Western countries.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Otorhinolaryngology
Lauren T. Roland, Alan Regenberg, Amber U. Luong, Sarah K. Wise, Elina Toskala, Kent K. Lam, Joshua M. Levy, Christine B. Franzese, Kristine Smith, Jean Kim
Summary: Biologics have been approved for use in chronic rhinosinusitis with nasal polyps patients, showing effectiveness in controlling the disease in both subjective and objective short-term outcomes. However, the high costs of biologics may pose a burden for the healthcare system with widespread and prolonged use. Cost-effectiveness analyses are needed to determine appropriate usage, along with addressing patient preferences, counseling on side effects, and healthcare economics.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Florent Carsuzaa, Emilie Bequignon, Xavier Dufour, Guillaume de Bonnecaze, Jean-Claude Lecron, Laure Favot
Summary: This review summarizes the current state of knowledge regarding the cytokine signature in CRSwNP, as well as the role of cytokines in the pathogenesis of the disease and in intercellular communication between epithelial cells, fibroblasts, and inflammatory cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Allergy
Caroline P. E. Price, Amina Guo, Whitney W. Stevens, Leslie Cousens, Thanh-Huyen T. Vu, Lydia A. Suh, Kristin A. Erickson, David Conley, Leslie C. Grammer, Robert C. Kern, Bruce K. Tan, Atsushi Kato, Robert P. Schleimer, Stephanie S. Smith, Kevin C. Welch, Anju T. Peters
Summary: The addition of AZD1981 to intranasal corticosteroids did not improve nasal polyp size, symptoms, or quality of life in adult patients with CRSwNP.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Review
Allergy
Joaquim Mullol, Antoine Azar, Kathleen M. Buchheit, Claire Hopkins, Jonathan A. Bernstein
Summary: This review summarizes the clinical evidence on quality of life outcomes with current treatments for CRSwNP up to 2021, and assesses the improvement in QoL after biologic treatments, especially for patients with reported comorbidities in interventional studies.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Allergy
Florian Vogt, Jagdeep Sahota, Therese Bidder, Rebecca Livingston, Helene Bellas, Simon B. Gane, Valerie J. Lund, Douglas S. Robinson, Harsha H. Kariyawasam
Summary: The study found that anxiety scores improved after treatment with omalizumab in patients with severe chronic rhinosinusitis and asthma, while depression scores did not show improvement.
CLINICAL AND TRANSLATIONAL ALLERGY
(2021)
Article
Cell Biology
Jian-Wen Ruan, Jie-Fang Zhao, Xue-Li Li, Bo Liao, Li Pan, Ke-Zhang Zhu, Qi-Miao Feng, Jin-Xin Liu, Zi-E Yu, Jia Song, Hai Wang, Zheng Liu
Summary: In chronic rhinosinusitis with nasal polyps (CRSwNP), tissue neutrophilia is associated with higher levels of inflammatory mediators and lower percentages of apoptotic neutrophils. Neutrophil-high nasal polyps predominantly exhibit type 1 and type 3 endotypes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Health Care Sciences & Services
Agamemnon Bakakos, Florence Schleich, Petros Bakakos
Summary: This review focuses on the correlation between asthma and nasal polyps, and evaluates the treatment efficacy of various monoclonal antibodies in patients with severe asthma and nasal polyps, as well as in patients with nasal polyps without asthma or with mild-to-moderate asthma. The selection of the right biologic agent becomes an important target, but is challenging due to the lack of comparative head-to-head studies.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Allergy
Junqin Bai, Julia H. Huang, Caroline P. E. Price, Jacob M. Schauer, Lydia A. Suh, Regan Harmon, David B. Conley, Kevin C. Welch, Robert C. Kern, Stephanie Shintani-Smith, Anju T. Peters, Whitney W. Stevens, Atsushi Kato, Robert P. Schleimer, Bruce K. Tan
Summary: This study aimed to evaluate the impact of polyp recurrence (PR) on disease severity post-ESS and quantify the prognostic value of various clinical variables and biomarkers. The study found a significant association between PR and radiographic and sinonasal test scores post-ESS. A combined model incorporating clinical and biomarker factors accurately predicted PR.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)